TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

IZERVAY

AVACINCAPTAD PEGOL SODIUM
Ophthalmology Approved 2023-08-04
2
Indications
--
Phase 3 Trials
1
Priority Reviews
2
Years on Market

Details

Status
Prescription
First Approved
2023-08-04
Routes
INTRAVITREAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: AVACINCAPTAD PEGOL SODIUM

IZERVAY Approval History

Loading approval history...

What IZERVAY Treats

2 indications

IZERVAY is approved for 2 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Geographic Atrophy
  • Age-Related Macular Degeneration
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IZERVAY FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

IZERVAY ™ is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). IZERVAY is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) .

IZERVAY Patents & Exclusivity

Latest Patent: Jul 2034

Patents (6 active)

US11491176 Expires Jul 11, 2034
US11273171 Expires Jul 11, 2034
US12016875 Expires Jul 11, 2034
US9617546 Expires Feb 14, 2027
US7579456 Expires Feb 14, 2027
US8236773 Expires Nov 11, 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.